Amikacin may be included in the treatment of MDR/RR-TB patients aged 18 years or more on
longer regimens when susceptibility has been demonstrated and adequate measures to monitor
for adverse reactions can be ensured. If amikacin is not available, streptomycin may replace
amikacin under the same conditions.
Guideline Citation
WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.